Member access

4-Traders Homepage  >  Shares  >  Xetra (Allemagne)  >  Addex Pharmaceuticals SA    APE   CH0029850754

 SummaryNewsCalendarCompanyFinancialsConsensusRevisionsForum 
Company
Sector
Biotechnology
Calendar
-
Surperformance© rating of Addex Pharmaceuticals SA
Trading Rating : Investor Rating :
More about the company
Financials ( CHF)
Sales 2013 0,28 M
EBIT 2013 -17,8 M
Net income 2013 -17,4 M
Debt 2013 0,41 M
Yield 2013 -
Sales 2014 0,20 M
EBIT 2014 -27,9 M
Net income 2014 -27,9 M
Debt 2014 -
Yield 2014 -
PER 2013 -
PER 2014
Capi. / Sales 2013 216x
Capi. / Sales 2014 296x
Capitalization 59,1 M
More Financials
Latest news on ADDEX PHARMACEUTICALS SA
3d ago ADDEX PHARMACEUTICALS SA: Validates Potential Efficacy Biomarker for Phase 1 Tr..
05/01 ADDEX THERAPEUTICS: Addex Reports that Dipragluant Demonstrated Dose-Dependent ..
05/01 ADDEX PHARMACEUTICALS SA: Reports that Dipragluant Demonstrated Dose-Dependent ..
04/30 ADDEX THERAPEUTICS: Addex Announces CFO, Tim Dyer, to Transition to External Co..
04/30 ADDEX PHARMACEUTICALS SA: Announces CFO, Tim Dyer, to Transition to External Co..
04/30 ADDEX THERAPEUTICS: Addex Reports ADX71441 Reduces Alcohol Intake in a Preclini..
04/30 ADDEX PHARMACEUTICALS SA: Reports ADX71441 Reduces Alcohol Intake in a Preclini..
04/24 ADDEX PHARMACEUTICALS SA: Receives Approval to Initiate a Phase 1, First-In-Man..
04/22 ADDEX THERAPEUTICS: Addex Announces Issuance of a Broad European Composition of..
04/22 ADDEX PHARMACEUTICALS SA: Announces Issuance of a Broad European Composition of..
04/18 ADDEX THERAPEUTICS: Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunct..
04/18 ADDEX PHARMACEUTICALS SA: Dipraglurant Normalizes Striatal Cholinergic Dysfunct..
More news
Forum ADDEX PHARMACEUTICALS SA
Advertisement
Income Statement Evolution
Addex Pharmaceuticals SA : Income Statement Evolution
More Financials
EPS Revisions
Addex Pharmaceuticals SA : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.